Context-Dependent GluN2B-Selective Inhibitors of NMDA Receptor Function Are Neuroprotective with Minimal Side Effects

Neuron

Volumn 85, Issue 6, 2015, Pages 1305-1318

  Yuan, Hongjie ^a   Myers, Scott J ^a   Wells, Gordon ^b   Nicholson, Katherine L ^c   Swanger, Sharon A ^a   Lyuboslavsky, Polina ^a   Tahirovic, Yesim A ^b   Menaldino, David S ^b   Ganesh, Thota ^a   Wilson, Lawrence J ^b   Liotta, Dennis C ^b   Snyder, James P ^b   Traynelis, Stephen F ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 BENZYL ALPHA (4 HYDROXYPHENYL) BETA METHYL 1 PIPERIDINEPROPANOL; AM 92016; APTIGANEL; DICARBOXYLIC ACID; DIZOCILPINE; GLUTAMATE RECEPTOR; IFENPRODIL; KETAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PHENCYCLIDINE; PROTEIN GLUN2B; UNCLASSIFIED DRUG; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROPROTECTIVE AGENT; NR2B NMDA RECEPTOR;

ACIDITY; ADVERSE DRUG REACTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING SITE; BRAIN ISCHEMIA; CONTROLLED STUDY; CRYSTAL STRUCTURE; DOSE RESPONSE; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG STRUCTURE; HUMAN; HUMAN CELL; IC50; IN VIVO STUDY; MALE; MOUSE; NEUROPROTECTION; NONHUMAN; PH; PRIORITY JOURNAL; TOXICITY TESTING; ANIMAL; ANTAGONISTS AND INHIBITORS; BRAIN; C57BL MOUSE; CHEMISTRY; DISEASE MODEL; DRUG EFFECTS; METABOLISM; STROKE;

ANIMALS; BRAIN; DISEASE MODELS, ANIMAL; HUMANS; HYDROGEN-ION CONCENTRATION; MALE; MICE, INBRED C57BL; NEUROPROTECTIVE AGENTS; RECEPTORS, N-METHYL-D-ASPARTATE; STROKE;

EID: 84925341678     PISSN: 08966273     EISSN: 10974199     Source Type: Journal    
DOI: 10.1016/j.neuron.2015.02.008     Document Type: Article

References (76)

1. Albers G.W., Goldstein L.B., Hall D., Lesko L.M. Aptiganel hydrochloride in acute ischemic stroke: a randomized controlled trial. JAMA 2001, 286:2673-2682. Aptiganel Acute Stroke Investigators.
2. Allen F.H. The Cambridge Structural Database: a quarter of a million crystal structures and rising. Acta Crystallogr. B 2002, 58:380-388.
3. Balster R.L., Willetts J. Receptor mediation of the discriminative stimulus properties of phencyclidine and sigma-opioid agonists. Psychopharmacol. Ser. 1988, 4:122-135.
4. Banke T.G., Dravid S.M., Traynelis S.F. Protons trap NR1/NR2B NMDA receptors in a nonconducting state. J.Neurosci. 2005, 25:42-51.
5. Benveniste M., Mayer M.L. Effect of extracellular pH on the potency of N-methyl-D-aspartic acid receptor competitive antagonists. Mol. Pharmacol. 1992, 42:679-686.
6. Bertorelli R., Adami M., Di Santo E., Ghezzi P. MK 801 and dexamethasone reduce both tumor necrosis factor levels and infarct volume after focal cerebral ischemia in the rat brain. Neurosci. Lett. 1998, 246:41-44.
7. Blagrove M., Morgan C.J.A., Curran H.V., Bromley L., Brandner B. The incidence of unpleasant dreams after sub-anaesthetic ketamine. Psychopharmacol. 2009, 203:109-120.
8. Bombarda E., Ullmann G.M. pH-dependent pKa values in proteins-a theoretical analysis of protonation energies with practical consequences for enzymatic reactions. J.Phys. Chem. B 2010, 114:1994-2003.
9. Burger P.B., Yuan H., Karakas E., Geballe M., Furukawa H., Liotta D.C., Snyder J.P., Traynelis S.F. Mapping the binding of GluN2B-selective N-methyl-D-aspartate receptor negative allosteric modulators. Mol. Pharmacol. 2012, 82:344-359.
10. Chang Y., Bruni R., Kloss B., Assur Z., Kloppmann E., Rost B., Hendrickson W.A., Liu Q. Structural basis for a pH-sensitive calcium leak across membranes. Science 2014, 344:1131-1135.
11. Chaperon F., Müller W., Auberson Y.P., Tricklebank M.D., Neijt H.C. Substitution for PCP, disruption of prepulse inhibition and hyperactivity induced by N-methyl-D-aspartate receptor antagonists: preferential involvement of the NR2B rather than NR2A subunit. Behav. Pharmacol. 2003, 14:477-487.
12. Chenard B.L., Menniti F.S. Antagonists selective for NMDA receptors containing the NR2B subunit. Curr. Pharm. Des. 1999, 5:381-404.
13. Choi D.W., Koh J.Y., Peters S. Pharmacology of glutamate neurotoxicity in cortical cell culture: attenuation by NMDA antagonists. J.Neurosci. 1988, 8:185-196.
14. Dawson D.A., Wadsworth G., Palmer A.M. A comparative assessment of the efficacy and side-effect liability of neuroprotective compounds in experimental stroke. Brain Res. 2001, 892:344-350.
15. De Vry J., Jentzsch K.R. Role of the NMDA receptor NR2B subunit in the discriminative stimulus effects of ketamine. Behav. Pharmacol. 2003, 14:229-235.
16. Diener H.C., AlKhedr A., Busse O., Hacke W., Zingmark P.H., Jonsson N., Basun H. Treatment of acute ischaemic stroke with the low-affinity, use-dependent NMDA antagonist AR-R15896AR. A safety and tolerability study. J.Neurol. 2002, 249:561-568. Study group.
17. Ellrén K., Lehmann A. Calcium dependency of N-methyl-D-aspartate toxicity in slices from the immature rat hippocampus. Neurosci. 1989, 32:371-379.
18. Farin A., Marshall L.F. Lessons from epidemiologic studies in clinical trials of traumatic brain injury. Acta Neurochir. Suppl. (Wien) 2004, 89:101-107.
19. Gielen M., Le Goff A., Stroebel D., Johnson J.W., Neyton J., Paoletti P. Structural rearrangements of NR1/NR2A NMDA receptors during allosteric inhibition. Neuron 2008, 57:80-93.
20. Gladstone D.J., Black S.E., Hakim A.M. Toward wisdom from failure: lessons from neuroprotective stroke trials and new therapeutic directions. Stroke 2002, 33:2123-2136. Heart and Stroke Foundation of Ontario Centre of Excellence in Stroke Recovery.
21. Hamill C.E., Mannaioni G., Lyuboslavsky P., Sastre A.A., Traynelis S.F. Protease-activated receptor 1-dependent neuronal damage involves NMDA receptor function. Exp. Neurol. 2009, 217:136-146.
22. Hansen K.B., Ogden K.K., Yuan H., Traynelis S.F. Distinct functional and pharmacological properties of Triheteromeric GluN1/GluN2A/GluN2B NMDA receptors. Neuron 2014, 81:1084-1096.
23. Harris T.K., Turner G.J. Structural basis of perturbed pKa values of catalytic groups in enzyme active sites. IUBMB Life 2002, 53:85-98.
24. Hatfield R.H., Gill R., Brazell C. The dose-response relationship and therapeutic window for dizocilpine (MK-801) in a rat focal ischaemia model. Eur. J. Pharmacol. 1992, 216:1-7.
25. Hatton C.J., Paoletti P. Modulation of triheteromeric NMDA receptors by N-terminal domain ligands. Neuron 2005, 46:261-274.
26. Humphrey W., Dalke A., Schulten K. VMD: visual molecular dynamics. J.Mol. Graph. 1996, 14:33-38. 27-28.
27. Jasti J., Furukawa H., Gonzales E.B., Gouaux E. Structure of acid-sensing ion channel 1 at 1.9 A resolution and low pH. Nature 2007, 449:316-323.
28. Junge C.E., Sugawara T., Mannaioni G., Alagarsamy S., Conn P.J., Brat D.J., Chan P.H., Traynelis S.F. The contribution of protease-activated receptor 1 to neuronal damage caused by transient focal cerebral ischemia. Proc. Natl. Acad. Sci. USA 2003, 100:13019-13024.
29. Kaplan J., Dimlich R.V., Biros M.H., Hedges J. Mechanisms of ischemic cerebral injury. Resuscitation 1987, 15:149-169.
30. Karakas E., Furukawa H. Crystal structure of a heterotetrameric NMDA receptor ion channel. Science 2014, 344:992-997.
31. Karakas E., Simorowski N., Furukawa H. Structure of the zinc-bound amino-terminal domain of the NMDA receptor NR2B subunit. EMBO J. 2009, 28:3910-3920.
32. Karakas E., Simorowski N., Furukawa H. Subunit arrangement and phenylethanolamine binding in GluN1/GluN2B NMDA receptors. Nature 2011, 475:249-253.
33. Katsura K., Siesjo B. Acid-base metabolism in ischemia. pH and Brain Function 1998, 563. Wiley-Liss, New York. K. Kaila, B.R. Ransom (Eds.).
34. Katsura K., Asplund B., Ekholm A., Siesjö B.K. Extra- and intracellular pH in the brain during ischaemia, related to tissue lactate content in normo- and hypercapnic rats. Eur. J. Neurosci. 1992, 4:166-176.
35. Kidwell C.S., Liebeskind D.S., Starkman S., Saver J.L. Trends in acute ischemic stroke trials through the 20th century. Stroke 2001, 32:1349-1359.
36. Lee C.H., Lü W., Michel J.C., Goehring A., Du J., Song X., Gouaux E. NMDA receptor structures reveal subunit arrangement and pore architecture. Nature 2014, 511:191-197.
37. Lees K.R., Asplund K., Carolei A., Davis S.M., Diener H.C., Kaste M., Orgogozo J.M., Whitehead J. Glycine antagonist (gavestinel) in neuroprotection (GAIN International) in patients with acute stroke: a randomised controlled trial. Lancet 2000, 355:1949-1954. GAIN International Investigators.
38. Leiserowitz L., Harris T.K., Turner G.J. Molecular packing modes. Carboxylic acids. Acta Crystallogr. B 2002, 53:85-98.
39. Low C.M., Lyuboslavsky P., French A., Le P., Wyatte K., Thiel W.H., Marchan E.M., Igarashi K., Kashiwagi K., Gernert K., et al. Molecular determinants of proton-sensitive N-methyl-D-aspartate receptor gating. Mol. Pharmacol. 2003, 63:1212-1222.
40. Macrae C.F., Edgington P.R., McCabe P., Pidcock E., Shields G.P., Taylor R., Towler M., van de Streek J. Mercury: visualization and analysis of crystal structures. J.Appl. Cryst. 2006, 39:453-457.
41. Matsumoto T., Obrenovitch T.P., Parkinson N.A., Symon L. Cortical activity, ionic homeostasis, and acidosis during rat brain repetitive ischemia. Stroke 1990, 21:1192-1198.
42. Mody I., MacDonald J.F. NMDA receptor-dependent excitotoxicity: the role of intracellular Ca2+ release. Trends Pharmacol. Sci. 1995, 16:356-359.
43. Morris G.F., Bullock R., Marshall S.B., Marmarou A., Maas A., Marshall L.F. Failure of the competitive N-methyl-D-aspartate antagonist Selfotel (CGS 19755) in the treatment of severe head injury: results of two phase III clinical trials. J.Neurosurg. 1999, 91:737-743. The Selfotel Investigators.
44. Mosley C.A., Myers S.J., Murray E.E., Santangelo R., Tahirovic Y.A., Kurtkaya N., Mullasseril P., Yuan H., Lyuboslavsky P., Le P., et al. Synthesis, structural activity-relationships, and biological evaluation of novel amide-based allosteric binding site antagonists in NR1A/NR2B N-methyl-D-aspartate receptors. Bioorg. Med. Chem. 2009, 17:6463-6480.
45. Mott D.D., Doherty J.J., Zhang S., Washburn M.S., Fendley M.J., Lyuboslavsky P., Traynelis S.F., Dingledine R. Phenylethanolamines inhibit NMDA receptors by enhancing proton inhibition. Nat. Neurosci. 1998, 1:659-667.
46. Muir K.W. Glutamate-based therapeutic approaches: clinical trials with NMDA antagonists. Curr. Opin. Pharmacol. 2006, 6:53-60.
47. Mutch W.A., Hansen A.J. Extracellular pH changes during spreading depression and cerebral ischemia: mechanisms of brain pH regulation. J.Cereb. Blood Flow Metab. 1984, 4:17-27.
48. Narayan R.K., Michel M.E., Ansell B., Baethmann A., Biegon A., Bracken M.B., Bullock M.R., Choi S.C., Clifton G.L., Contant C.F., et al. Clinical trials in head injury. J.Neurotrauma 2002, 19:503-557.
49. Nedergaard M., Kraig R.P., Tanabe J., Pulsinelli W.A. Dynamics of interstitial and intracellular pH in evolving brain infarct. Am. J. Physiol. 1991, 260:R581-R588.
50. Nicholson K.L., Mansbach R.S., Menniti F.S., Balster R.L. The phencyclidine-like discriminative stimulus effects and reinforcing properties of the NR2B-selective N-methyl-D-aspartate antagonist CP-101 606 in rats and rhesus monkeys. Behav. Pharmacol. 2007, 18:731-743.
51. Nutt J.G., Gunzler S.A., Kirchhoff T., Hogarth P., Weaver J.L., Krams M., Jamerson B., Menniti F.S., Landen J.W. Effects of a NR2B selective NMDA glutamate antagonist, CP-101,606, on dyskinesia and Parkinsonism. Mov. Disord. 2008, 23:1860-1866.
52. Olney J.W. Brain lesions, obesity, and other disturbances in mice treated with monosodium glutamate. Science 1969, 164:719-721.
53. Olsson M. PROPKA3: consistent treatment of internal and surface residues in empirical pKa predictions. J.Chem. Theory Comput. 2011, 7:525-537.
54. Pahk A.J., Williams K. Influence of extracellular pH on inhibition by ifenprodil at N-methyl-D-aspartate receptors in Xenopus oocytes. Neurosci. Lett. 1997, 225:29-32.
55. Preskorn S.H., Baker B., Kolluri S., Menniti F.S., Krams M., Landen J.W. An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder. J.Clin. Psychopharmacol. 2008, 28:631-637.
56. Ritschel T., Hoertner S., Heine A., Diederich F., Klebe G. Crystal structure analysis and insilico pKa calculations suggest strong pKa shifts of ligands as driving force for high-affinity binding to TGT. ChemBioChem 2009, 10:716-727.
57. Rowland L.M. Subanesthetic ketamine: how it alters physiology and behavior in humans. Aviat. Space Environ. Med. 2005, 76(Suppl):C52-C58.
58. Sacco R.L., DeRosa J.T., Haley E.C., Levin B., Ordronneau P., Phillips S.J., Rundek T., Snipes R.G., Thompson J.L. Glycine antagonist in neuroprotection for patients with acute stroke: GAIN Americas: a randomized controlled trial. JAMA 2001, 285:1719-1728. Glycine Antagonist in Neuroprotection Americas Investigators.
59. Saver J.L. The 2012 Feinberg Lecture: treatment swift and treatment sure. Stroke 2013, 44:270-277.
60. Sherman W., Day T., Jacobson M.P., Friesner R.A., Farid R. Novel procedure for modeling ligand/receptor induced fit effects. J.Med. Chem. 2006, 49:534-553.
61. Shipman S.T., Douglass P.C., Yoo H.S., Hinkle C.E., Mierzejewski E.L., Pate B.H. Vibrational dynamics of carboxylic acid dimers in gas and dilute solution. Phys. Chem. Chem. Phys. 2007, 9:4572-4586.
62. Smith M.L., von Hanwehr R., Siesjö B.K. Changes in extra- and intracellular pH in the brain during and following ischemia in hyperglycemic and in moderately hypoglycemic rats. J.Cereb. Blood Flow Metab. 1986, 6:574-583.
63. Sussman F., Villaverde M.C., Domínguez J.L., Danielson U.H. On the active site protonation state in aspartic proteases: implications for drug design. Curr. Pharm. Des. 2013, 19:4257-4275.
64. Tahirovic Y.A., Geballe M., Gruszecka-Kowalik E., Myers S.J., Lyuboslavsky P., Le P., French A., Irier H., Choi W.B., Easterling K., et al. Enantiomeric propanolamines as selective N-methyl-D-aspartate 2B receptor antagonists. J.Med. Chem. 2008, 51:5506-5521.
65. Traynelis S.F., Hartley M., Heinemann S.F. Control of proton sensitivity of the NMDA receptor by RNA splicing and polyamines. Science 1995, 268:873-876.
66. Tzeli D., Theodorakopoulos G., Petsalakis I.D., Ajami D., Rebek J. Theoretical study of hydrogen bonding in homodimers and heterodimers of amide, boronic acid, and carboxylic acid, free and in encapsulation complexes. J.Am. Chem. Soc. 2011, 133:16977-16985.
67. Vance K.M., Simorowski N., Traynelis S.F., Furukawa H. Ligand-specific deactivation time course of GluN1/GluN2D NMDA receptors. Nat. Commun. 2011, 2:294.
68. Vasileiou C., Lee K.S., Crist R.M., Vaezeslami S., Goins S.M., Geiger J.H., Borhan B. Dissection of the critical binding determinants of cellular retinoic acid binding protein II by mutagenesis and fluorescence binding assay. Proteins 2009, 76:281-290.
69. Wang H., James M.L., Venkatraman T.N., Wilson L.J., Lyuboslavsky P., Myers S.J., Lascola C.D., Laskowitz D.T. pH-sensitive NMDA inhibitors improve outcome in a murine model of SAH. Neurocrit. Care 2014, 20:119-131.
70. Wood P.L. The NMDA receptor complex: a long and winding road to therapeutics. IDrugs 2005, 8:229-235.
71. Wroge C.M., Hogins J., Eisenman L., Mennerick S. Synaptic NMDA receptors mediate hypoxic excitotoxic death. J.Neurosci. 2012, 32:6732-6742.
72. Xiao F., Pardue S., Arnold T., Carden D., Alexander J.S., Monroe J., Sharp C.D., Turnage R., Conrad S. Effect of ifenprodil, a polyamine site NMDA receptor antagonist, on brain edema formation following asphyxial cardiac arrest in rats. Resuscitation 2004, 61:209-219.
73. Yang Y., Li Q., Yang T., Hussain M., Shuaib A. Reduced brain infarct volume and improved neurological outcome by inhibition of the NR2B subunit of NMDA receptors by using CP101,606-27 alone and in combination with rt-PA in a thromboembolic stroke model in rats. J.Neurosurg. 2003, 98:397-403.
74. Young D. Computational Chemistry: A Practical Guide or Applying Techniques to Real World Problems 2001, 330. Wiley-Interscience, New York.
75. Yuan H., Hansen K.B., Vance K.M., Ogden K.K., Traynelis S.F. Control of NMDA receptor function by the NR2 subunit amino-terminal domain. J.Neurosci. 2009, 29:12045-12058.
76. Yurkewicz L., Weaver J., Bullock M.R., Marshall L.F. The effect of the selective NMDA receptor antagonist traxoprodil in the treatment of traumatic brain injury. J.Neurotrauma 2005, 22:1428-1443.